• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单细胞测序在急性髓系白血病中的应用

Single-cell sequencing applications in acute myeloid leukemia.

作者信息

Lecornec Nicolas, Duchmann Matthieu, Itzykson Raphael

机构信息

Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Université Paris Cité, Paris, France.

Département d'Immuno-Hématologie Pédiatrique, Hôpital Robert-Debré, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.

出版信息

Leuk Lymphoma. 2025 Feb;66(2):175-189. doi: 10.1080/10428194.2024.2422833. Epub 2024 Nov 4.

DOI:10.1080/10428194.2024.2422833
PMID:39496597
Abstract

Acute myeloid leukemia (AML) is a heterogeneous group of malignancies with poor prognosis. AML result from the proliferation of immature myeloid cells blocked at a variable stage of differentiation. Beyond inter-patient heterogeneity, AMLs are characterized by genetic and phenotypic intra-patient heterogeneity. Despite major advances in deciphering AML biology with bulk sequencing studies, pivotal questions remain unanswered. Analyses at the single-cell level could thus transform our understanding of these neoplasms. We review recent progresses in single-cell sequencing technologies from cell processing to bioinformatic pipelines. We next discuss how single-cell applications have helped understand the genetic and functional intra-leukemic heterogeneity, emphasizing aspects related to leukemic stem cells, clonal evolution and measurable residual disease (MRD) monitoring. We finally delineate how single-cell technologies could be implemented in routine clinical practice to improve patient management.

摘要

急性髓系白血病(AML)是一组预后不良的异质性恶性肿瘤。AML 由在不同分化阶段受阻的未成熟髓系细胞增殖所致。除了患者间的异质性外,AML 的特征还在于患者内部的基因和表型异质性。尽管通过大量测序研究在解读 AML 生物学方面取得了重大进展,但关键问题仍未得到解答。因此,单细胞水平的分析可能会改变我们对这些肿瘤的理解。我们回顾了从细胞处理到生物信息学流程的单细胞测序技术的最新进展。接下来,我们讨论单细胞应用如何有助于理解白血病内部的基因和功能异质性,重点强调与白血病干细胞、克隆进化和可测量残留病(MRD)监测相关的方面。我们最后阐述了单细胞技术如何能够在常规临床实践中实施以改善患者管理。

相似文献

1
Single-cell sequencing applications in acute myeloid leukemia.单细胞测序在急性髓系白血病中的应用
Leuk Lymphoma. 2025 Feb;66(2):175-189. doi: 10.1080/10428194.2024.2422833. Epub 2024 Nov 4.
2
Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.伴有突变的急性髓系白血病中的微小残留病监测:临床观点和展望。
Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.
3
A single-cell survey of cellular hierarchy in acute myeloid leukemia.急性髓系白血病中细胞层次结构的单细胞调查。
J Hematol Oncol. 2020 Sep 25;13(1):128. doi: 10.1186/s13045-020-00941-y.
4
Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.白血病干细胞在急性髓系白血病中的相关性:异质性及其对疾病监测、预后和治疗设计的影响
Expert Rev Hematol. 2014 Dec;7(6):791-805. doi: 10.1586/17474086.2014.959921. Epub 2014 Sep 22.
5
Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.在急性髓系白血病中的下一代测序的临床实用性。
Mol Diagn Ther. 2020 Feb;24(1):1-13. doi: 10.1007/s40291-019-00443-9.
6
Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.非 M3 急性髓系白血病中基因改变作为微小残留病灶标志物的临床价值。
Hematology. 2021 Dec;26(1):848-859. doi: 10.1080/16078454.2021.1990503.
7
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.在 AML 患者进行异基因造血细胞移植前,通过 NGS 进行可测量残留病监测。
Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.
8
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.急性髓系白血病中克隆特异性微小残留病的精准度及预后价值
Haematologica. 2017 Jul;102(7):1227-1237. doi: 10.3324/haematol.2016.159681. Epub 2017 Mar 16.
9
Novel Tools for Diagnosis and Monitoring of AML.新型 AML 诊断和监测工具。
Curr Oncol. 2023 May 23;30(6):5201-5213. doi: 10.3390/curroncol30060395.
10
Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.急性髓细胞白血病的生物标志物、治疗方法及相关挑战的最新进展。
Ann Hematol. 2024 Nov;103(11):4375-4400. doi: 10.1007/s00277-024-05963-x. Epub 2024 Aug 29.